Skip to main content

Table 3 Results of multivariate Cox regression analysis according to occurrence of re-bleeding

From: HCC portal hypertension imaging score derived from CT predicts re-bleeding and mortality after acute variceal bleeding

Variables

Univariate in variceal bleeding (n = 195)

 

Multivariat in variceal bleeding (n = 195)

 

Hazard Ratio (95% CI)

P-value

Hazard Ratio (95% CI)

P-value

Age (years)

0.988 (0.964–1.012)

0.318

  

Gender (male vs. female)

1.679 (0.986–2.858)

0.056

  

Child-Pugh score

1.300 (1.201–1.408)

< 0.001

1.080 (0.959–1.216)

0.202

MELD (score)

1.178 (1.107–1254)

< 0.001

0.978 (0.889–1.076)

0.646

BMI (kg/m2)

0.874 (0.749–1.020)

0.088

  

BCLC stage, A/B/C/D, n (%)

3.013 (2.198–4.131)

< 0.001

  

Maximum tumor size, cm, mean ± SD

1.132 (1.019–1.257)

0.021

  

Multifocal tumor, n (%)

2.685 (1.581–4.561)

< 0.001

  

Extent of portal vein tumor thrombus Grade I/ Grade II/ Grade III/Grade IV, n (%)

1.899(1.584–2.277)

< 0.001

  

Size of EV ≥ 4 mm/Size of EV < 4 mm, n (%)

3.097 (1.962–4.887)

< 0.001

  

Prior overt hepatic encephalopathy, n (%)

3.932 (2.237–6.913)

< 0.001

0.550 (0.238–1.274)

0.163

Ascites, n (%)

1.156 (0.418–3.199)

0.779

  

ALT (IU/L)

1.002(0.996–1.008)

0.506

  

AST (IU/L)

1.011 (1.003–1.020)

0.011

1.008 (0.997–1.018)

0.148

Prothrombin time (s)

0.910 (0.780 − 0.061)

0.228

  

Serum albumin (g/l)

1.006 (0.966–1.048)

0.783

  

Total bilirubin (µmol/l)

1.004 (0.998–1.009)

0.226

  

Platelet count (×109/mm3)

0.008 (1.002–1.015)

0.009

1.004 (0.997–1.010)

0.268

HCCPHTIS

2.277 (1.881–2.757)

< 0.001

2.330 (1.728–3.142)

< 0.001

  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona clinic liver cancer; BMI, body mass index; CI, confidence interval; EV, esophageal varices; HCC, hepatocellular carcinoma; HCCPHTIS, hepatocellular carcinoma portal hypertension imaging score; MELD, model for end-stage liver disease; PVTT, portal vein tumor thrombus